The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
38
No.
46
December 14, 2012
CCL
Vol.
35
No.
12
December 28, 2012
- Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response
- Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease
- Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival
- Volasertib Shows Response In 31 Percent of Acute Myeloid Leukemia Patients
- Breast Cancer Risk Increases With Repeated CT Imaging
- Scatter Radiation from Mammography Presents No Increased Cancer Risk
- MRI, 3D Ultrasound Combination Can Guide Prostate Biopsies
- Perifosine, Sorafenib Combination Well Tolerated in Several Lymphomas
- NCI-Approved CTEP Trials For the Month of December
- FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer